Sign In
Buy FAMDF
$0.0090
-0.0004 (-4.66%)
At Close: Jun 03, 2026
Futura Medical shares climb on upbeat revenue forecast and cash position
04:37am, Wednesday, 04'th Feb 2026
Futura Medical PLC (AIM:FUM, OTC:FAMDF, FRA:GYX) shares rose as much as 10% in early trading after the company said it expects to report revenue of £1.7...
Futura Medical lifts full-year revenue forecast ahead of strategic review
02:39am, Wednesday, 04'th Feb 2026
Futura Medical PLC (AIM:FUM, OTC:FAMDF, FRA:GYX), the consumer healthcare company behind erectile dysfunction gel Eroxon, expects to report revenue of £1.7 million for 2025, exceeding earlier guidanc
Analysts look to 'cyclicals' as inflexion point approaches
10:06am, Monday, 12'th Jan 2026
In terms of sector themes, JP Morgan is sticking with “the cyclicals”, arguing the backdrop for 2026 looks increasingly supportive as the growth–inflation...
Nasdaq, S&P 500 higher as investors brush off Fed independence concerns, gold surges
08:45am, Monday, 12'th Jan 2026
1:45pm: In the green The three major stock indexes all edged into positive territory in the early afternoon as investors shrugged off Fed independence...
US bank urges investors to look beyond the calm... and into small and mid-caps
08:33am, Monday, 12'th Jan 2026
JPMorgan has kicked off the year with a broadly positive outlook for global equities in 202, but with a note of caution. The investment bank said markets...
Futura Medical jumps 11% on promising early data for female sexual health gel
06:01am, Monday, 12'th Jan 2026
Shares in Futura Medical PLC (AIM:FUM, OTC:FAMDF) rose 11% to 1.45p on Monday after the company unveiled positive early-stage trial results for a new gel...
Corero Network Security shares advance on trading boost
05:33am, Monday, 12'th Jan 2026
Corero Network Security PLC (AIM:CNS, OTCQB:DDOSF) shares climbed higher on Monday, after the firm told investors it expects revenue for FY 2025 to reach...
Futura hails ‘highly significant’ trial results for female sexual health gel
02:28am, Monday, 12'th Jan 2026
Futura Medical PLC (AIM:FUM, OTC:FAMDF), the company behind the over-the-counter erectile dysfunction gel Eroxon, has announced encouraging early trial...
S&P 500 nears record close as Fed cuts rates, Russell notches new high
11:19am, Wednesday, 10'th Dec 2025
4:15pm: Markets cheer Fed cut US markets closed higher on Wednesday following the Federal Reserve’s decision to cut interest rates by 25 basis points in its...
Futura wins Chinese patent approval for Eroxon
02:46am, Wednesday, 10'th Dec 2025
Futura Medical PLC (AIM:FUM, OTC:FAMDF)has secured patent protection in China for its erectile dysfunction gel Eroxon, a move the company says should strengthen its hand as it looks for commercial par
Futura Medical board change sees non-exec step down
03:15am, Wednesday, 03'rd Dec 2025
Futura Medical PLC (AIM:FUM, OTC:FAMDF) has announced the resignation of Harmesh Suniara as non-executive director. The departure follows a reduction in...
Futura Medical secures £2.75m in new investment to push ahead with product development
02:37am, Thursday, 13'th Nov 2025
Futura Medical PLC (AIM:FUM, OTC:FAMDF) has turned to the market for fresh investment, raising £2.75 million with a share issue as it works to stabilise the business and push forward with new sexual
Futura Medical plc (FAMDF) Q2 2025 Earnings Call Transcript
03:42pm, Wednesday, 01'st Oct 2025
Futura Medical plc (OTC:FAMDF) Q2 2025 Earnings Call September 30, 2025 4:30 AM EDT Company Participants Alexander James Duggan Angela Hildreth - COO, Finance Director, Company Secretary & Executive D
Futura chief takes measured approach to strategic review
03:15am, Tuesday, 30'th Sep 2025
Futura Medical PLC's (AIM:FUM, OTC:FAMDF) new chief executive has said he is taking a patient and careful approach to a strategic review of the business, stressing there is significant value in its tw
Futura considers restructuring as sales disappoint
02:47am, Friday, 19'th Sep 2025
Futura Medical PLC (AIM:FUM, OTC:FAMDF) has widened its strategic review after warning that revenues next year will come in well below forecasts and that its cash is likely to run out early in 2026. T
